For Healthcare Start-Ups
From idea to scalable,
deployable healthcare product.
Not generic consulting. Surgeon-led, regulation-aware, execution-focused guidance — from someone who has built the products, filed the patents, navigated the regulators, and scaled the ventures.
MedTech · Medical Devices
Regulatory Strategy (FDA · CDSCO · CE)
AI Healthcare
IPR & Patent Strategy
Global Scaling
01 —
Who this is for
This is not for every startup. Only for those building real, deployable healthcare solutions — and who are serious about doing it right.
Healthcare founders with a clinical problem to solve
You have identified a genuine gap in how healthcare is delivered. You need to know if it is buildable, fundable, and deployable at scale.
Teams stuck between prototype and real-world adoption
The device works in the lab. But it hasn't been validated clinically, cleared regulatorily, or adopted by a single hospital. That gap is where most startups die.
Founders navigating regulatory uncertainty
FDA 510(k), CDSCO Class II, CE marking — regulatory strategy chosen at the wrong moment costs years and millions. The right pathway changes everything.
Institutions converting research into products
Academic labs, hospital innovation cells, and R&D teams sitting on promising ideas that need a structured commercial pathway from concept to company.
02 —
What makes this different
Most advisors operate in theory. This guidance is built from real products, real patents, and real execution.
Clinical + engineering + regulatory — in one room
No handoffs between a "clinical advisor" and a "regulatory consultant". The insight is integrated, because building products integrates all three simultaneously.
Class III to Class II pathway conversion
Knowing how to redesign a concept so it qualifies for a lower regulatory class is a specialist skill. It can cut time-to-market by 18 months and development cost by 60%.
Real hospital and international networks
Connections to Chief Medical Officers, hospital procurement committees, and health-tech ecosystems in India, the Middle East, and internationally.
Ethics are non-negotiable
I have walked away from ventures where success required compromising integrity. That same standard applies to every founder I work with — because shortcuts in healthcare have consequences.
03 —
How I work with founders
Every engagement follows a structured, execution-first approach — not open-ended advising sessions.
1
Problem Validation
Identifying real clinical gaps — not theoretical ideas
Before building anything, the clinical need must be verified by clinicians in actual practice. Many startups skip this and build for a problem that doesn't exist at scale, or that the healthcare system has already solved differently.
2
Proof of Concept
Testing with clinicians before scaling development
Clinical validation before significant capital is deployed. Physician feedback loops, prototype testing in real settings, and honest assessment of usability — before engineering doubles down on the wrong version.
3
Regulatory Strategy
Choosing the fastest viable pathway to market
FDA 510(k), CDSCO Class II, CE marking — the strategy must be decided early, not after the product is built. Redesigning for a lower regulatory class, where clinically appropriate, can save years and significant cost.
4
Product Development
Aligning engineering with clinical usability and safety
A product that works in an engineering lab but fails in a clinical environment is a failure. Development is guided by how the device will actually be used — by a nurse at 3am, in a resource-limited setting, under pressure.
5
IPR & Protection
Ensuring defensibility and long-term commercial value
Global patents are not just legal protection — they are a commercial asset and a signal of seriousness to investors and partners. Filing at the right moment, for the right claims, in the right markets is a strategic decision.
6
Deployment & Scaling
From pilot programme to real-world adoption
Hospital adoption, distribution networks, international market entry, caregiver trust — a great product that nobody uses is a failure. This final stage is where most health-tech ventures stall, and where clinical credibility opens doors that commercial pitches cannot.
04 —
What gets built
Not ideas — but scalable, deployable healthcare solutions with real clinical adoption pathways.
Medical devices
Class I and II devices with global applicability — designed for clinical usability, regulatory compliance, and cost-effective manufacture from day one.
AI-based diagnostic platforms
Early detection of cancers, cardiac events, glaucoma — AI/ML solutions that have clinical validation and a clear integration pathway into existing hospital workflows.
IoT-enabled monitoring systems
Remote patient monitoring, IV fluid safety, vital sign surveillance — hardware-software integrated solutions that reduce clinical burden and cross-infection risk.
Hospital-grade scalable technologies
Disinfection, infection control, surgical visualisation — technologies validated at hospital grade, with international regulatory clearance and proven deployment records.
Affordable access innovations
Products designed specifically to reduce cost barriers in low-resource settings — without compromising clinical precision. The 60% cost reduction achieved in video laryngoscopy is the benchmark.
Sustainable health-tech ventures
Waste-to-energy, environmental health, bio-conversion — healthcare innovation that aligns public health outcomes with environmental sustainability and long-term commercial viability.
05 —